Company / Revenue
CytomX Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$76.2M
FY2025
5-year range
$37.3M / $138.1M
FY2021-FY2025
Trend
-44.8%
vs FY2024
Sector context
#111 of 155
Health Care
What the data says
At $76M, CytomX Therapeutics, Inc.'s revenue ranks #111 of 155 in the Health Care sector. Revenue has fluctuated over the past 10 years, ranging from $15M in FY2016 to $138M in FY2024.
Based on SEC 10-K filings.
$76M in FY2025 with a 5-year CAGR of -5.4%.
Declined from $101M to $76M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- -5.4%
- 10-Year CAGR
- -
Sector benchmark
#111 of 155 in Health CareTop 72% of 155This company $76.2M Sector average $4.5B
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.4%, indicating a declining trend.
- In FY2025, revenue decreased 44.8% year-over-year.
- Ranks #111 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $76.2M | -44.8% |
| FY2024 | $138.1M | +36.4% |
| FY2023 | $101.2M | +90.4% |
| FY2022 | $53.2M | +42.5% |
| FY2021 | $37.3M | -62.8% |
| FY2020 | $100.4M | +74.6% |
| FY2019 | $57.5M | -3.4% |
| FY2018 | $59.5M | -16.9% |
| FY2017 | $71.6M | +376.1% |
| FY2016 | $15.0M | +1594.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026